Garon EB, Spira AI, Goldberg SB, Chaft JE, Papadimitrakopoulou V, Antonia SJ, et al. Safety and activity of durvalumab + tremelimumab in immunotherapy ( IMT)-pretreated advanced NSCLC patients. ASCO 2018; Abstract 9041.